A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

Marisa Tungsiripat, Douglas Kitch, Marshall J. Glesby, Samir K. Gupta, John W. Mellors, Laura Moran, Lynne Jones, Beverly Alston-Smith, James F. Rooney, Judith A. Aberg

Research output: Contribution to journalArticle

66 Scopus citations

Abstract

Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.

Original languageEnglish (US)
Pages (from-to)1781-1784
Number of pages4
JournalAIDS
Volume24
Issue number11
DOIs
StatePublished - Jul 17 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206'. Together they form a unique fingerprint.

  • Cite this

    Tungsiripat, M., Kitch, D., Glesby, M. J., Gupta, S. K., Mellors, J. W., Moran, L., Jones, L., Alston-Smith, B., Rooney, J. F., & Aberg, J. A. (2010). A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS, 24(11), 1781-1784. https://doi.org/10.1097/QAD.0b013e32833ad8b4